Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc.

Gossamer Bio ( ($GOSS) ) has provided an update. On July 1, 2026, Gossamer Bio announced the initial conversion rate for its 7.50% Convertible Seni...

Gossamer Bio Sets Conversion Terms for Convertible Notes

The latest update is out from Gossamer Bio ( ($GOSS) ). On June 17, 2026, Gossamer Bio announced the final results of its exchange offer and consen...

Gossamer Bio Announces Final Convertible Notes Exchange Results

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, slipped 0.28% at Tuesday’s open. Oil prices fell again, pul...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GOSS	$0.17	-3.03%	12.93M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GOSS	$0.17	-3.0%	12.93M
3
4
5
6

GOSS

GOSS

Get Gossamer Bio Inc. Data in Excel

Get Gossamer Bio Inc. Data in Excel